PacBio Files 8-K/A Amendment on Officer/Director Changes

Ticker: PACB · Form: 8-K/A · Filed: Feb 7, 2025 · CIK: 1299130

Sentiment: neutral

Topics: leadership-change, officer-appointment, director-election, compensation

Related Tickers: PACB

TL;DR

PacBio amended its 8-K, reporting leadership shakeups and compensation changes effective Jan 24.

AI Summary

Pacific Biosciences of California, Inc. filed an amendment (8-K/A) on February 7, 2025, reporting changes effective January 24, 2025. The filing concerns the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers.

Why It Matters

This amendment to a previous filing indicates significant changes in the company's leadership structure and executive compensation, which could impact strategic direction and investor confidence.

Risk Assessment

Risk Level: medium — Changes in key leadership and executive compensation can signal internal shifts or strategic realignments that may carry inherent business risks.

Key Players & Entities

FAQ

What specific officer or director positions were affected by this amendment?

The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' but does not specify the names or exact roles in the provided excerpt.

What is the effective date of the reported changes?

The earliest event reported is dated January 24, 2025.

When was this amendment filed with the SEC?

This amendment was filed as of February 7, 2025.

What type of SEC filing is this?

This is a Form 8-K/A, an amendment to a current report.

What is the primary business of Pacific Biosciences of California, Inc.?

The company is involved in 'LABORATORY ANALYTICAL INSTRUMENTS' with SIC code 3826.

Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-02-07 17:08:35

Key Financial Figures

Filing Documents

From the Filing

pacb-20250124 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2025 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O'Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. Pacific Biosciences of California, Inc. (the "Company") is filing this amendment to its Current Report on Form 8-K filed on January 30, 2025, which reported that the Company's Board of Directors (the "Board") had appointed Christopher M. Smith as a new director of the Company. At the time of his appointment, Mr. Smith was not appointed to any Board committee. On February 6, 2024, upon the recommendation of the Corporate Governance and Nominating Committee of the Board, the Board appointed Mr. Smith to the Science and Technology Committee of the Board, effective immediately. In connection with his appointment to the Science and Technology Committee, Mr. Smith will receive additional cash compensation as set forth in the Company's non-employee director compensation policy, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2024. Concurrent with such appointment, upon the recommendation of the Corporate Governance and Nominating Committee of the Board, the Board appointed Marshall Mohr as chairman of the Audit Committee of the Board in place of Randy Livingston, who will continue to serve as a member of the Audit Committee. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Brett Atkins Brett Atkins General Counsel Date: February 7, 2025

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on Read The Filing